AU2021255884A1 - Anti-FLT3 antibodies and compositions - Google Patents

Anti-FLT3 antibodies and compositions Download PDF

Info

Publication number
AU2021255884A1
AU2021255884A1 AU2021255884A AU2021255884A AU2021255884A1 AU 2021255884 A1 AU2021255884 A1 AU 2021255884A1 AU 2021255884 A AU2021255884 A AU 2021255884A AU 2021255884 A AU2021255884 A AU 2021255884A AU 2021255884 A1 AU2021255884 A1 AU 2021255884A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
nos
flt3
acid sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021255884A
Other languages
English (en)
Inventor
Randi Westh Hansen
Trine Lindsted
Eva Maria Carlsen MELANDER
Mikkel Wandahl Pedersen
Matteo RIVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of AU2021255884A1 publication Critical patent/AU2021255884A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021255884A 2020-04-14 2021-04-14 Anti-FLT3 antibodies and compositions Pending AU2021255884A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009578P 2020-04-14 2020-04-14
US63/009,578 2020-04-14
PCT/EP2021/059646 WO2021209495A1 (en) 2020-04-14 2021-04-14 Anti-flt3 antibodies and compositions

Publications (1)

Publication Number Publication Date
AU2021255884A1 true AU2021255884A1 (en) 2022-11-17

Family

ID=75530015

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021255884A Pending AU2021255884A1 (en) 2020-04-14 2021-04-14 Anti-FLT3 antibodies and compositions

Country Status (16)

Country Link
US (2) US12252539B2 (https=)
EP (1) EP4136114A1 (https=)
JP (1) JP7679399B2 (https=)
KR (1) KR20220167331A (https=)
CN (1) CN115715297A (https=)
AU (1) AU2021255884A1 (https=)
BR (1) BR112022020683A2 (https=)
CA (1) CA3180188A1 (https=)
CL (1) CL2022002833A1 (https=)
CO (1) CO2022014520A2 (https=)
IL (1) IL297269A (https=)
MX (1) MX2022012919A (https=)
PE (1) PE20230075A1 (https=)
PH (1) PH12022552710A1 (https=)
TW (1) TWI910146B (https=)
WO (1) WO2021209495A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI910146B (zh) * 2020-04-14 2026-01-01 法商施維雅藥廠 抗flt3抗體及組合物
WO2024108163A2 (en) * 2022-11-18 2024-05-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to cd135 polypeptides
EP4637816A1 (en) * 2022-12-22 2025-10-29 The Medical College of Wisconsin, Inc. Compositions that target cd138 and cd3 and methods of making and using the same
IL325858A (en) * 2023-07-12 2026-03-01 Phenomic Ai Mediators of T cell activation against CTHRC1 and methods of using them
CN118924724B (zh) * 2024-07-29 2025-11-04 湖南大学 一种用于治疗神经母细胞瘤的药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7832394A (en) 1993-09-08 1995-03-27 Imclone Systems Incorporated Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
MXPA03003632A (es) 2000-10-24 2003-09-10 Immunex Corp Metodo para tratamiento de tumores usando terapia de combinacion.
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
HRP20160422T1 (hr) * 2009-12-23 2016-05-20 Synimmune Gmbh Protutijela protiv flt3 postupci njihove upotrebe
CA2961950A1 (en) * 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
TWI829617B (zh) * 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
AU2017382883B2 (en) * 2016-12-21 2024-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
CN118772278A (zh) * 2017-06-02 2024-10-15 辉瑞公司 Flt3的特异性抗体及其用途
JP7317718B2 (ja) * 2017-06-02 2023-07-31 ファイザー・インク Ｆｌｔ３を標的にするキメラ抗原受容体
CN113056486B (zh) * 2018-09-11 2025-06-17 德国肿瘤研究中心 改善的抗flt3抗原结合蛋白
JP7642542B2 (ja) * 2018-12-18 2025-03-10 ベーリンガー・インゲルハイム・イオ・カナダ・インコーポレイテッド Ｆｌｔ３アゴニスト抗体及びその使用
TWI910146B (zh) * 2020-04-14 2026-01-01 法商施維雅藥廠 抗flt3抗體及組合物

Also Published As

Publication number Publication date
TW202200620A (zh) 2022-01-01
PE20230075A1 (es) 2023-01-11
US12252539B2 (en) 2025-03-18
CA3180188A1 (en) 2021-10-21
WO2021209495A1 (en) 2021-10-21
CN115715297A (zh) 2023-02-24
JP2023522630A (ja) 2023-05-31
BR112022020683A2 (pt) 2022-11-29
MX2022012919A (es) 2022-11-16
CO2022014520A2 (es) 2022-11-08
TWI910146B (zh) 2026-01-01
CL2022002833A1 (es) 2023-06-09
US20210317216A1 (en) 2021-10-14
US20250179195A1 (en) 2025-06-05
EP4136114A1 (en) 2023-02-22
IL297269A (en) 2022-12-01
KR20220167331A (ko) 2022-12-20
PH12022552710A1 (en) 2024-03-25
JP7679399B2 (ja) 2025-05-19

Similar Documents

Publication Publication Date Title
US11834503B2 (en) Anti-lag-3 antibodies and compositions
US11634500B2 (en) Anti-CD73 antibodies and compositions
US11034765B2 (en) Anti-PD-1 antibodies and compositions
US12252539B2 (en) Anti-FLT3 antibodies and compositions
US12012450B2 (en) Anti-NKG2A antibodies and compositions
US11807688B2 (en) Anti-AXL antibodies and compositions
US20210214454A1 (en) Anti-cd40 antibodies and compositions
RU2836004C1 (ru) Антитела и композиции против flt3
EA052808B1 (ru) Антитела и композиции против flt3
HK40084729A (en) Anti-flt3 antibodies and compositions
BR122025028949A2 (pt) Usos de: anticorpos anti-flt3, composição farmacêutica, molécula de ligaçâo biespecífica
HK40106092A (zh) 抗nkg2a抗体和组合物